Equibles does not estimate personal net worth.
Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ANIK alertsStephen Griffin is recorded as CFO at Anika Therapeutics, Inc. (ANIK) since June 3, 2024. Anika Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Stephen Griffin was appointed Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024. Stephen Griffin has spoken on 1 earnings call across 1 company, most recently for Anika Therapeutics, Inc. on November 6, 2026. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Cheryl Blanchard (CEO and Board Member), Stephen (Steve) Griffin (CEO and Board Member), Stephen D. Griffin (CEO, CFO and Board Member) and 7 others.
“On May 8, 2024, Anika Therapeutics, Inc. (the “Company”) announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024 (the “Effective Date”), replacing Michael Levitz, who tendered his resignation on May 2, 2024”
“Our third quarter performance marked another positive step in building a stronger, more profitable Annika. Revenue grew 10% with growth in both our commercial and OEM channels.”
2024-06-03–present
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
2024-06-03–present
